Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?

Author： Fecher Leslie A.   Flaherty Keith T.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.7, Iss.3, 2009-03, pp. : 295-304

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

By Sabel Michael S.   Sondak Vernon K.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 1, 2004-01 ,pp. : 61-68

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma

By Lewis Karl   Samlowski Wolfram   Ward John   Catlett Joseph   Cranmer Lee   Kirkwood John   Lawson David   Whitman Eric   Gonzalez Rene  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 161-166

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

By Juergens Rosalyn A.   Brahmer Julie R.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 6, 2006-07 ,pp. : 595-600

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Sargramostim: potential adjuvant therapy in melanoma?

By  

Inpharma, Vol. 1, Iss. 1240, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Agatolimod [PF-3512676] has potential as an adjuvant therapy in malignant melanoma

By  

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite